摘要
目的:探究喉咽清颗粒联合布地奈德在急性上呼吸道感染患儿中的应用效果。方法:选取2023年4月—2024年4月株洲市二医院收治的120例急性上呼吸道感染患儿作为研究对象,以随机数字表法分为对照组、观察组,各60例。对照组采取常规治疗联合布地奈德治疗,观察组在对照组基础上联合喉咽清颗粒治疗。比较两组症状消失时间、炎性因子水平、不良反应发生率。结果:观察组发热、肺啰音、咳嗽及咽喉肿痛消失时间短于对照组(P<0.001);观察组白细胞介素-8、白细胞介素-6、C反应蛋白、肿瘤坏死因子-α水平低于对照组(P<0.05);观察组不良反应发生率低于对照组(P=0.015)。结论:在急性上呼吸道感染患儿的治疗中,喉咽清颗粒联合布地奈德可促进临床症状缓解,减轻炎性反应,降低不良反应发生率。
Objective:To explore the application effect of Houyanqing granules combined with budesonide in children with acute upper respiratory tract infection.Methods:A total of 120 children with acute upper respiratory tract infection admitted to Zhuzhou Second Hospital from April 2023 to April 2024 were selected as the study subjects.They were divided into control group and observation group according to random number table method,with 60 cases in each group.The control group was treated with conventional therapy combined with budesonide,and the observation group was treated with Houyanqing granules on the basis of the control group.The symptom disappearance time,the levels of inflammatory factors,and the incidence of adverse reactions were compared between the two groups.Results:The disappearance time of fever,pulmonary rales,cough,and sore throat in the observation group was shorter than that in the control group(P<0.001).The levels of interleukin-8,interleukin-6,C-reactive protein and tumor necrosis factor-αin the observation group were lower than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P=0.015).Conclusion:In the treatment of children with acute upper respiratory tract infection,Houyanqing granules combined with budesonide can promote the relief of clinical symptoms,alleviate inflammatory response,and reduce the incidence of adverse reactions.
作者
王英玲
Wang Yingling(Zhuzhou Second Hospital,Zhuzhou 412000,Hunan Province,China)
出处
《中外医药研究》
2025年第31期120-122,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
关键词
喉咽清颗粒
布地奈德
急性上呼吸道感染
炎性因子
儿童
Houyanqing granules
Budesonide
Acute upper respiratory tract infection
Inflammatory factor
Children
